secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2021-09-01T23:59:59+00:00
Accession:  0001193125-21-263316
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata appoints Kyri Van Hoose as CFO; Thomas Insley resigns, becomes consultant
--------------------------------------------------------------------------------

- Kyri Van Hoose appointed SVP, CFO effective Sept 1, 2021; previously CFO at TEGA Therapeutics.
- Thomas Insley resigned as CFO but remains as financial consultant via consulting agreement.
- Van Hoose granted stock options for 75,000 shares at $5.39, vesting over 48 months from Oct 1, 2021.
- Insley served as CFO for 6 years; transition supports continued development of DMT310 and DMT410.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000119312521263316/0001193125-21-263316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000119312521263316/d227068d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-263316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer